Seer (NASDAQ:SEER) reported lower first-quarter revenue but reaffirmed its full-year 2026 outlook, with management pointing to population-scale proteomics studies, an expanding publication base and expected second-half consumables demand as supports for the year.
Total revenue for the quarter ended March 31, 2026, was $2.8 million, down from $4.2 million in the first quarter of 2025. Chief Executive Officer and Chair Omid Farokhzad said the quarter reflected “the ongoing depressed academic funding environment” that has pressured customer budgets, as well as increased competitive activity from what he described as “inferior product imitators.”
